J. Chim

Most-cited papers

1. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

   A. Palumbo, O. Sezer, R. Kyle, J. Miguel +33 more

   2009Leukemia151 citations Open access

   Semantic Scholar

   Save

2. Treatment of relapsed acute promyelocytic leukemia by arsenic-based strategies without hematopoietic stem cell transplantation in Hong Kong: a seven-year experience

   Wing-Yan Au, J. Chim, A. Lie, C. Kumana +5 more

   20048 citations

   Semantic Scholar

   Save

3. Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group

   Wen-Ming Chen, Zhen Cai, J. Chim, W. Chng +11 more

   2025Clinical Hematology International7 citations

   Semantic Scholar

   Save

4. Frequent methylation of the tumor suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification

   Lu-Qiang Wang, Shaji K. Kumar, G. Calin, Zhenhai Li +1 more

   2019Clinical Lymphoma, Myeloma & Leukemia2 citations

   Semantic Scholar

   Save

5. Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.

   J. H. Lee, Kihyun Kim, Jin Seok Kim, Chang-Ki Min +16 more

   20122 citations

   Semantic Scholar

   Save

6. 3-weekly Daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma

   J. Chim, V. Wong, Eyl Au, Yok-Lam Kwong

   2019Clinical Lymphoma, Myeloma & Leukemia1 citations

   Semantic Scholar

   Save

7. Standardized minimal residual disease detection by next generation sequencing in multiple myeloma

   Qiumei Yao, Yinlei Bai, A. Órfão, J. Chim

   2019Clinical Lymphoma, Myeloma & Leukemia1 citations

   Semantic Scholar

   Save

8. Upgraded standardized minimal residual disease detection by next generation sequencing in multiple myeloma

   Qiumei Yao, J. Chim

   2019Clinical Lymphoma, Myeloma & Leukemia1 citations

   Semantic Scholar

   Save

9. Assessment of tumor burden in multiple myeloma by correlation between dual-tracer PET/CT and {beta}2-microglobulin

   C. Ho, Si-Rong Chen, Kam-Chau Cheng, Y. Leung +3 more

   20131 citations

   Semantic Scholar

   Save

10. Added value of 11C-acetate PET/CT to 18F-FDG for the management of myeloma

    C. Ho, Si-Rong Chen, T. Cheng, J. Chim +2 more

    20121 citations

    Semantic Scholar

    Save

11. Advances in the Treatment of Multiple Myeloma: Long Awaited

    J. Chim

    20071 citations

    Semantic Scholar

    Save

12. 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma.

    J. Chim, V. Wong, E. Au, Yok-Lam Kwong

    2019Journal of Clinical Oncology0 citations

    Semantic Scholar

    Save

13. Comparative study between 11C-acetate and 18F-FDG PET/CT in the detection of diffuse type of multiple myeloma

    C. Ho, Si-Rong Chen, Y. Leung, Kam-Chau Cheng +3 more

    20130 citations

    Semantic Scholar

    Save

14. To optimise myeloma treatment in the era of targeted therapy

    J. Chim

    20110 citations

    Semantic Scholar

    Save

15. New modalities that enable detection of occult bone disease include magnetic resonance imaging of the bone marrow and positron emission tomography scan

    J. Chim, R. L. iang

    20090 citations

    Semantic Scholar

    Save

16. Epigenetic Therapy Comes of Age: Waking Up Silenced Tumour Suppressor Genes in Myelodysplastic Syndrome

    J. Chim

    20080 citations

    Semantic Scholar

    Save